preview earn highlight key catalyst
clinic commerci compani expect mostli in-lin
qs tsro potenti miss
data data parp pdufa
earn preview key catalyst watch preview
earn commercial-stag compani highlight key pipelin updat
catalyst focus clinical-stag compani coverag
commerci takeaway includ expect tsro
sale gener in-lin vs estim consensu think
could risk ocaliva sale base im script trend below-
consensu revenu potenti compound compani escal financ
overhang expect investor focu remain emerg safeti concern
follow dear hcp letter fda safeti commun issu
septemb anticip label chang ocaliva expect earli
potenti initi phase nash trial cirrhot patient kerx
note im script trend auryxia track consensu though
focu like anticip uptak follow label expans
novemb anoth consecut quarter expect report
meaning trifer calcitriol revenu instead tri focu investor
compani effort reconsid exclud trifer dialysi
bundl pass unlik develop view
expect quarter contain sever import clinic data readout
potenti includ phase data trial epacadostat
keytruda melanoma one import late-stag clinic data
readout smid-cap univers continu confid
data especi given risk/reward current level believ share
could trade rang success outcom trade
trial fail could also see phase data
trial astrazeneca/merck lynparza brca frontlin ovarian
cancer mainten success data readout potenti pressur tsro
although doc recent doc day event skeptic
success trial conduct exclus brca patient
would lead label usag broader group patient regulatori
catalyst expect includ anticip pdufa ferahem
label expans broad iron defici anemia februari well
pdufa subcutan makena auto-injector februari
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
incy- ow pt highlight smid-cap
outlook avail made one top overweight pick
base assess risk/reward compani phase
trial epacadostat melanoma one import binari
event year smid-cap univers top-line result trial
expect continu confid success readout
base prior data earlier trial also anticip result phase
studi ruxolitinib steroid-refractori acut graft versu host
diseas gvhd
jakafi/iclusig model us jakafi revenu in-lin consensu
company-provid impli yoy growth roughli
sale recal sale aid slight increas
inventori build channel manag estim account
benefit sale model iclusig revenu slightli
ahead consensu total revenu estim
includ olumi royalti mileston revenu ahead
current consensu though believ consensu like mix
account mileston expect recogn quarter
includ payment novarti relat jakavi sale
payment relat baricitinib phase trial initi atop derm
expect focu jakafi revenu outlook includ
introduct financi guidanc year continu view strong
commerci execut import part stori provid solid
foundat advanc pipelin drug discoveri engin
 ow pt follow present detail
phase trial data american societi hematolog
meet decemb expect limit focu earn ahead
potenti regulatori decis label expans pdufa set may
manag comment suggest adcetri revenu guidanc
provid earn call though expect
includ revenu sale indic therefor unlik
materi stock believ possibl manag may choos
guid conserv last year though expect mute impact
share investor await fda action label expans
repres much larger potenti opportun earn call
listen commerci updat adcetri includ potenti
compendia list base data sign off-label sale
set follow present detail data
american societi hematolog confer decemb strateg
updat plan regard use adc combin i/o agent
adcetri model adcetri sale impli yoy growth
gener in-lin consensu bloomberg total revenu
estim mostli line consensu current adcetri
sale main focu investor expans opportun
front-lin hodgkin lymphoma hl provid significantli fundament
potenti strateg valu share
tesaro tsro ow pt tsro share pressur
follow concern slow growth guidanc overal parp
competit dynam size parp market investor fear
astrazeneca/merck lynparza pois domin ovarian cancer
beyond compani report zejula sale in-lin
consensu though guidanc impli growth flat qoq
disappoint investor hope reassur continu strong growth
face increas competit
concern set-up quarter even
stock week low given view palpabl frustrat amongst
investor number level believ focu like tangibl
result well guidanc tsro share increasingli becom show
stori may take time evolv potenti upsid beat
may mute chang commerci dynam face azn/mrk
trial readout brca frontlin ovarian cancer mainten expect
clovi rubraca potenti label expans pdufa date
april ovarian cancer mainten set zejula
lynparza current compet expect share support
level given expand natur potenti multi-blockbust class
though chang competit dynam may limit upsid investor
clear understand size ovarian cancer market
competit profil zejula vs parp impact
downstream parp use ovarian cancer includ line mainten
set whether parp plu io reach fruition whether parp parp
viabl addit percept consensu estim still
high think risk tsro may provid conserv
 believ zejula sale like meet consensu model
sale quarter in-lin bloomberg consensu
howev expect investor like focu competit
commentari long-term outlook given increas competit
lynparza potenti rubraca label expans well develop
timelin expens
averag prescript
new therapi
patient base new patient start
gross-to-net adjust approx
exist patient assum discontinu rate vs total patient
estim varubi sale total revenu varubi
consensu in-lin total revenu consensu
bloomberg import varubi revenu quarter
comment revis label dear hcp letter
call listen updat data commentari address
competit dynam ovarian cancer market overal size
market reimburs environ zejula includ free drug
account zejula volum current futur
anticip competit dynam three approv parp especi
given recent expand lynparza label anticip label expans
rubraca also anticip detail review develop program
zejula plu io new phase trial plan frontlin ovarian cancer
mainten compar zejula zejula monotherapi second-lin
treatment compar zejula avastin vs chemo similar avanova
compani also plan phase trial zejula nsclc regardless
express phase trial combin patient high pd-
express also watch data phase quadra
studi treatment could provid import data valid parp
 ow pt tsro share also
pressur face increas competit azn/mrk lynparza
concern overal size ovarian market parp recent
intrinsiq market data provid tesaro show zejula lynparza share gain
ovarian cancer market come expens rubraca limit
current brca treatment label fda decis date april
potenti expand rubraca label broad mainten set
zejula lynparza current compet believ investor expect
sale growth quarter larg temper expect focu
direct toward regulatori progress europ whether
compani expect advisori committe meet ahead april pdufa
base patient flow model believ could report
sale sell-side consensu expect bloomberg model
revenu essenti flat vs model assum flat new
patient start patient progress quarterli discontinu rate
rang stabl assumpt impli number
prescript per patient free drug dispens gross-to-net adjust
exhibit
similar tsro expect investor like focu updat develop
program timelin specif believ investor look
addit inform around plan athena trial frontlin ovarian
cancer mainten given race frontlin posit
third compani explor frontlin mainten use among parp
intercept uw pt anticip signific newsflow intercept
first quarter investor focus label updat ocaliva
updat regard initi phase nash trial cirrhot patient
financi outlook compani also possibl compani could
provid enrol updat on-going trial regener nash
cobalt pbc follow dear hcp letter fda safeti commun
septemb ocaliva see note compani guidanc
suggest updat label earli believ investor focus
magnitud scope potenti chang label black box
warn contraind increas monitor restrict certain
subgroup chanc fda could decid conven adcom
implement risk evalu mitig strategi rem address safeti
declin pbc sale im health symphoni monthli prescript data show
modest declin total new prescript ocaliva see exhibit
suggest potenti risk sale estim
roughli in-lin consensu bloomberg im weekli data
suggest prescript may dispens track toward
assum similar captur rate gross-to-net adjust seen
previou quarter recal report world-wide net ocaliva
revenu includ revenu ocaliva net revenu
also includ one-tim increas relat chang revenu
account methodolog sell-in method account see note
detail compani also report revenu ex-u sale
ocaliva prescript audit data ocaliva sale outsid
 limit visibl intern sale also acknowledg
level inventori channel separ variabl could impact
prescript captur via audit remain believ intern
sale would approxim doubl meet consensu
exhibit quarterli ocaliva new total prescript
expens guidanc cash runway import face financ overhang
importantli first full quarter prescript data follow
septemb dear hcp letter fda safeti commun relat ocaliva
given declin prescript seen us expect investor
focu manag commentari regard outlook prescrib trend
ocaliva sale well expens guidanc especi stock
year low compani histor provid adjust oper
expens guidanc exclud non-cash item stock-bas compens
depreci includ ocaliva ex-u
commerci ramp continu compani initi phase nash
cirrhot trial believ possibl compani sg expens
grow estim compani may year end
suggest quarter cash runway current burn rate ocaliva
revenu pressur current potenti futur safeti
commun expens guidanc exce current estim cash
runway may meaning shorter believ financ overhang may
keep investor sidelin complic effort rais capit
stock current level
keryx kerx ew pt expect investor keenli focus
auryxia sale quarter attent paid evolv commerci
dynam ie gross-to-net adjust initi feedback uptak follow
label expans treatment iron defici anemia chronic kidney
diseas ckd novemb recal kerx announc fda approv
label expans well earn novemb
favor auryxia label overshadow revenu miss well
compani withdrawn guidanc see note auryxia sale
impact higher expect gross-to-net adjust driven primarili
chang payor mix volum move medicar part plan
command greater rebates/discount kerx share also pressur
lower revenu greater uncertainti magnifi compani financ
overhang keryx end cash equival
convert debt share outstand
view im prescript auryxia appear track consensu
bloomberg approxim auryxia prescript
dispens accord im health key factor impact auryxia
net revenu percentag prescript fill via specialti pharmaci
davita rx freseniu rx captur retail prescript
audit gross-to-net revenu adjust histor
auryxia volum fill via specialti pharmaci gross-to-net
adjust histor rang although
jump manag comment suggest expect
remain high low rang remaind
follow tabl provid sensit analysi expect auryxia revenu
base im weekli prescript data variabl
listen call evolv commerci dynam auryxia
given higher-than-anticip gross-to-net adjust withdrawn
revenu guidanc initi feedback uptak auryxia expans
indic financi guidanc revenu expens
busi develop progress compani highlight
strateg prioriti expect investor continu watch potenti
impact introduct gener renvela use auryxia dialysi
announc gener in-lin preliminari result provid initi
guidanc suggest potenti upsid current consensu see takeaway
note howev major near-term regulatori commerci catalyst
anticip februari includ pdufa date ferahem label
expans caus iron-defici anemia feb potenti
gener entri intramuscular im makena follow loss exclus loe
feb pdufa date sc makena feb believ investor
take wait-and-se approach initi guidanc manag
comment suggest introduct im makena gener repres
largest swing factor initi guidanc rang depend time
number gener competitor previous note invest thesi
predic robust makena demand rather busi
support durabl grow base franchis ferahem cbr
potenti underappreci growth asset intrarosa see continu
invest intrarosa necessari invest build drug
potenti franchis view support august
survey ob/gyn show physician view drug
posit differenti anticip prescrib patient
dyspareunia peak detail avail septemb initi report
believ investor focu begin shift intrarosa potenti well
continu growth valu base busi follow key
catalyst februari provid greater visibl expect
durabl makena franchis
rockwel uw pt recent name one top
underweight pick base expect share continu
struggl absenc transit payment statu trifer lack
meaning trifer revenu inabl commerci gener calcitriol
receiv approv june yet launch see
outlook model total revenu consist
base hemodialysi concentr busi
recognit baxter/wanbang up-front payment compani
earn call rockwel acknowledg trifer origin deni pass
statu januari lobbi underway
determin revers remain skeptic given lack demand
date consult extern expert believ
like scenario trifer qualifi pass-through payment statu
given iron product fall exist anemia manag
function categori alreadi reimburs bundl payment dialysi
rockwel continu issu work manufactur
difficulti gener calcitriol origin approv june
yet launch recent guidanc suggest fda request
addit time review calcitriol post-approv drug manufactur
submiss decis anticip listen
call updat pass-through payment statu potenti
price trifer updat fda decis commerci plan
gener calcitriol approv june yet
launch futur trifer develop plan
pick ahead phase data luspatercept top-line result
md trial medalist beta thalassemia trial believ
expect read see outlook note believ
investor continu becom engag stori ahead
part phase trial fshd show promis activ
increas muscl size though question remain drug impact
muscl function key program acceleron also plan initi
phase trial recent reacquir asset sotatercept pulmonari arteri
hypertens pah view program encourag await
clinic data attribut valu model
result phase studi vadadustat japan dialysi ckd patient
well initi phase develop program japan led
partner mitsubishi tanab see takeaway note compani
continu enrol global phase trial vadadustat dialysi
pre-dialysi patient initi data expect akebia anticip
complet enrol program data
enabl potenti nda file addit phase
trial hyporespond underway data expect also
plan initi phase studi test weekli tiw dose
earli data potenti major vadadustat catalyst
expect around near term catalyst expect driven
competitor data includ roxadustat multipl data readout
throughout catalyz posit data report success execut
across compani pipelin includ clinic stage program across
indic share perform avapritinib develop
profil gist better expect activ kit driven patient
superl data advanc system mastocytosi sm addit share
respond increas investor confid ret inhibitor ahead
clinic proof concept spur competit data loxo
view de-risk class believ share like
continu strength present first human data
call investor like focu regulatori clariti
path forward indol sm updat gist hepatocellular
carcinoma expect compani may provid updat
regulatori pathway gist could serv catalyst share
 ow pt initi coverag januari
ow rate pt see initi report base view
tazemetostat inhibitor demonstr impress efficaci
minim toxic sever blood cancer solid tumor see tazemetostat
reach blockbust statu forecast peak revenu
specif view compel data tazemetostat thu far
seen patient follicular lymphoma fl mutat
object respons rate orr monotherapi
believ tazemetostat use dlbcl drug produc less
compel monotherapi result viabl prefer view dlbcl potenti
upsid instead see fl primari opportun drug safeti
toler profil make well-suit use frontlin mainten
valuat driven use fl valuat
attribut dlbcl quarter listen updat data
readout time includ tazemetostat combin data rituxan
prednisolon tecentriq well clariti around regulatori
pathway tazemetostat fl
gw pharma gwph ow pt follow posit data present
american epilepsi societi meet decemb success
submiss epidiolex nda octob anticip investor focu
quarter epidiolex regulatori updat potenti topic may
discuss fda advisori committe meet adcomm expect
conven march/april also anticip updat commerci
prepar ahead potenti fda approv june separ
also expect data phase trial cbdv adult patient
refractori epilepsi could potenti expand gwph stori
beyond epidiolex use sever pediatr epilepsi
nabriva nbrv ow pt yesterday initi coverag nbrv
ow rate pt base confid success lefamulin
upcom phase leap trial result expect spring view
commerci opportun lefamulin underappreci level
initi report nabriva key asset lefamulin first-in-class
system pleuromutilin antibiot initi develop treatment
potenti indic septemb nabriva report posit
top-line data phase leap trial iv oral lefamulin show non-
inferior vs establish competit regimen see gradual
sale ramp new class drug believ lefamulin view
highli differenti establish nich patient high risk develop
resist infect see peak sale view stock
significantli under-valued level
 ew pt remain cautiou share
follow juli complet respons letter dextenza recent
manag chang ceo transit cfo/cmo/cco departur recal
downgrad share ew june given string manag
departur uncertainti ahead juli pdufa see note
given uncertainti around dextenza program execut turnov
would buyer share new manag team
shown abil execut oper strateg note
compani end cash invest compani
expect financ oper earn call
listen updat dextenza program step taken address
manufactur issu updat potenti nda resubmiss timelin
rhythm pharma ew pt initi coverag
ew rate pt octob see initi report base
view setmelanotid demonstr compel efficaci two
ultra-orphan indic pomc lepr defici believ key
long invest thesi lie increas confid setmelanotid success
beyond pomc lepr specif see key lever valuat
near term announc full enrol phase pomc
trial expect derisk bb indic also
anticip initi phase data setmelanotid expans opportun
alstrm syndrom pomc hetz
class month review design nda resubmiss
believ investor disappoint class review
follow manag comment suggest label discuss
remain continu see polar argument bull view
procedur necess given amount new inform submit support
nda bear specul could issu
applic beyond singl approv issu disclos origin
complet respons letter would necessit longer review
timelin continu see eventu approv like
see residu regulatori uncertainti assum probabl success
risk consensu expect drug launch peak compani
also submit nda treatment vasomotor
symptom vm decemb anticip nda accept march
potenti pdufa date octob time approv commerci
remain key stori opportun repres
valu model quarter expect investor focu updat
regulatori progress two applic well updat pre-
commerci activ expect polar argument volatil
share persist market assess regulatori risk
commerci opportun appear converg assess pt
remain sidelin pend addit certainti around regulatori
pathway visibl commerci launch
versarti vsar ew pt versarti announc result phase
veloc studi septemb show somavaratan fail
demonstr non-inferior pediatr growth hormon defici pghd vs
daili growth hormon intent-to-treat popul see takeaway
note await updat compani regard path forward
somavaratan altern strateg direct
zealand pharma a/ zeal- ow pt continu view main valu
driver zealand peptid pipelin repres risk-
adjust valu model support royalti backbon sanofi
partner diabet product main valu driver model
glepaglutid zealand potenti differenti develop
short bowel syndrom sb zealand conduct pharmacokinet pk trial
glepaglutid investig potenti once-weekli dose data
anticip believ weekli version glepaglutid could offer
compel differenti vs current market leader gattex may present
patient meaning reason chang therapi allow drug access
establish patient pool view potenti signific catalyst
zeal share zealand also run phase immunogen trial
dasiglucagon data expect expect investor focu
updat develop timelin peptid pipelin product also
anticip zeal share may react sanofi earn call commentari
around diabet market competit outlook
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
cash flow deriv pt assign probabl
factor drug/condit reflect clinic regulatori
risks/tim sum risk-adjust npv add cash excess
increment data releas luspatercept md beta-th continu
demonstr clinic meaning efficaci clean safeti profil increas
confid success program scenario assum
probabl success increas md beta-th
acceler advanc wholli own muscl franchis
acceleron asset continu progress phase program near
complet luspatercept md beta-th coordin partner
celgen base scenario assum luspatercept probabl success
md beta-thalassemia base scenario also includ
tgf-beta myelofibrosi muscl franchis ace-
safeti efficaci issu emerg tgf-beta class drug scenario
assum failur md possibl success lower probabl
success remain indic beta-th also assum
limit advanc wholli own pipelin
increment data de-risk drive share
increment data de-risk drive share
overweight acceleron given
believ compani tgf-beta platform
novel better way treat anemia
md mf
multipl compound demonstr
favor proof concept
luspatercept
demonstr proof concept human
luspatercept current phase
forecast luspatercept could
commerci earli
celgen partnership valid
platform celgen fund
commerci favor
financi term acceleron includ
substanti mileston royalti
addit celgen sharehold
compani think commit
help valid platform
key valu driver perceiv clinic
regulatori risk luspatercept
initi phase trial luspatercept
lower risk frontlin md
top-lin result phase luspatercept
trial md beta-th
risk achiev price
new safeti issu emerg
luspatercept
luspatercept fail phase trial md
beta-th
clinic failur muscl franchis
price target includ royalti sale luspatercept
myelodysplast syndrom md beta-thalassemia well valu tgf-beta
develop myelofibrosi mf wholly-own muscl franchis
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate line typic
development-stag biotechnolog compani reliant larg partner fund
advanc lead clinic program
termin growth rate model forecast revenu expens
opportun appli multipl cash flow account
termin valu asset
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin vari commerci assumpt base/bull/bear
case assum wacc termin valu
cash flow deriv pt assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
profil without safeti toler issu probabl
success indic scenario assum
product differenti profil commerci appeal
allow compet effect vs roxadustat ckd
dialysi model higher sale ckd current
project dialysi
vadadustat continu show meaning efficaci signific
safeti issu meaning differenti vs roxadustat
probabl success vadadustat non-dialysi ckd
dialysi vadadustat revenu primarili driven
ckd set peak sale vs peak sale
overweight ahead
upcom catalyst includ first
potenti phase data vadadustat
studi late
vadadustat safeti follow lack
signific safeti issu phase dialysi
data confid drug
safeti profil believ read-out
like eas concern mani investor
worri imbal advers
event death seen phase non-
demonstr viabil dialysi indic
three time weekli dose arm
phase dialysi trial appear
demonstr efficaci compar
daili dose commerci import
opportun dialysi indic extern
consult express prefer
anemia drug could start pre-
dialysi patient continu
advanc dialysi
main valuat driver
perceiv clinic regulatori risk
vadadustat ckd dialysi set
initi phase tiw trial earli
initi phase oncolog
risk achiev price
vadadustat demonstr lack efficaci
signific safeti issu emerg lead
program discontinu
eu patent offic rule akebia
composit matter patent
akebia opposit
roxadustat phase studi ckd
signific differenti vs vadadustat
vadadustat fail advanc clinic due lack efficaci
emerg signific safeti concern trade toward net
cash valu estim per share
price target includ sale vadadustat ckd dialysi well
mileston royalti payment vadadustat sale partner geographi
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate
termin growth rate model forecast revenu expens
opportun appli multipl nopat account
termin valu asset
solid base busi ferahem cbr look ahead intrarosa growth
solid base busi ferahem cbr look ahead intrarosa growth
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
best-cas scenario makena gener delay year
abl rapidli convert market subcutan makena follow
fda approv feb result peak makena sale
intrarosa launch exce expect quick adopt minim payor
pushback greater uptak peak sale ferahem usag
makena face gener competit multipl gener upon orphan
drug exclus expiri feb follow shortli thereaft introduct
compani subcutan auto-injector intrarosa see gradual launch
start acceler driven drug differenti attribut
increas physician awar see peak sale see
peak sale ferahem label expans broad success drive
increment peak revenu
worst-cas scenario multipl makena gener enter market
subcutan auto-injector makena never reach market intrarosa
launch disappoint and/or market dynam chang ie black box remov
local estrogen make product differenti less appeal
lead peak sale less ferahem gain broad
makena bear case larg price
investor focu anticip
loss orphan drug exclus ode
potenti life cycl extens makena
largest current sourc revenu
believ bear case larg price
show physician posit auto-
injector sens loyalti
brand intramuscular makena
proprietari scenario analysi show npv
makena franchis per share
base case per share worst case
scenario per share best case
intrarosa underappreci growth
driver alphawis ob/gyn survey
show strong posit differenti
steroid treat dyspareunia pain sex
view posit differenti
ob/gyn alphawis survey
peak usag expect
dyspareunia patient lack black box
warn signific posit differenti
factor think like drive uptak
patient concern long-term
use estrogen therapi and/or moder
risk breast cancer see peak sale
intrarosa higher current
consensu peak
cbr ferahem provid strong
revenue/npv backbon ferahem
blood registri cbr ferahem base
npv model ferahem label
expans broad fda
decis pdufa date feb repres
addit sale peak
share npv believ
reflect consensu today
key valuat driver commerci
execut approv drug makena
intrarosa ferahem cord blood
registri cbr servic well pipelin
advanc busi develop
weekly/monthli prescript track
fda decis pdufa ferahem label
fda decis pdufa subcutan
risk achiev price
multipl makena im gener
introduc lead faster-than-anticip
eros sale materi
ferahem label expans
materi sale fall short expect
pipelin advanc busi
develop valu destruct
pt includ us sale makena prevent pre-term birth intrarosa
dyspareunia ferahem treatment iron-defici anemia pre-dialysi
chronic kidney diseas label expans opportun all-caus cord
blood registri cbr servic model includ valu mugard oral
mucos remaind pipelin bremelanotid hypoact sexual
desir disord hsdd digoxin immun fab dif prevent preeclampsia
success either product repres upsid model
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate in-lin compani
histor wacc rest biopharmaceut univers commerci
termin growth rate model forecast revenu expens
opportun calcul termin valu cbr servic busi
million except per-shar data
mugard product sale royalti
licens fee collabor revenu
product sale
product revenu
servic
servic revenu
total revenu
total revenu
loss debt extinguish
multipl shot goal lead target therapi platform drug
multipl shot goal lead target therapi platform drug
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
nopat deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim
sum risk-adjust npv add cash excess requir
updat data present increasingli
compel show better-than-expect efficaci and/or safeti
toler probabl success po pdgfr kit-
driven gist system mastocytosi rise po
earli clinic data encourag drug profil gist
especi pdgfr subgroup model probabl success
us/eu peak sale gist
system mastocytosi model po model us/eu
sale assign probabl success model risk-
adjust npv earli pipelin drug discoveri engin
collabor roch
key valu driver
share inhibitor kit
pdgfr shown promis earli data
gist system mastocytosi data
patient pdgfr-driven gist appear
commerci pdgfr subgroup
gist assign probabl
success peak us/eu sale
repres
underappreci opportun
diseas rel treatment
option current avail drug
fairli ineffect poorli toler
blueprint present earli dose rang
data target
although safeti toler find
result tepid respons investor
believ may repres
underappreci opportun model
peak us/eu sale
probabl success
base extens librari uniqu
play role human pathophysiolog
allow develop highli select
kinas less off-target effect
gener control predict
side effect think drug discoveri
platform uniqu kinas librari add valu
potenti strateg option may
fulli appreci
updat clinic data present disappoint
paint less-compel profil gist sm probabl
key valuat driver perceiv
clinic regulatori commerci risk
pipelin asset blu-
success po fall pdgfr gist kit-driven gist sm
model less revenu kit-driven gist sm
initi clinic data ret
regulatori discuss defin
registr path sm
updat data gist
risk achiev price
clinic failur
due lack efficaci emerg
earlier stage pipelin fail advanc
collabor yield viabl
pt includ us europ sale pdgfr kit mutation-driven
gist system mastocytosi us/eu sale hepatocellular
carcinoma well us/eu sale ret-driven malign
valuat also includ risk-adjust npv blueprint
target drug discoveri platform earli pre-clin pipelin collabor
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
blueprint examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate in-lin compani
histor wacc rest development-stag biotechnolog univers
termin growth rate model forecast revenu expens
opportun beyond assign termin valu nopat
drug/opportun
exhibit risk-adjust valu molecul
player parp arena ovarian cancer backbon
player parp arena ovarian cancer backbon
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
nopat deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
rubraca becom prefer parp inhibitor second-lin mainten
drive stronger expect uptak ovarian cancer rubraca abl
expand breast prostat esophag cancer clovi success defend
rubraca ip estat past
follow success rubraca obtain broad label use ovarian
cancer mainten model rubraca split market share equal
astrazeneca tesaro model rubraca exclus
gener competit erod revenu
parp resist limit patient elig treatment rubraca fail
enter tumor type breast lung cancer rubraca patent
invalid gener competit enter earlier
rubraca abl carv viabl nich
ovarian cancer believ rubraca like
remain key drug line treatment
particularli reli
platinum-sensit expect rubraca
benefit eventu sequenti parp use
believ rubraca launch like
exceed expect less pill burden
toler issu compar lynparza
like label use
could benefit increas
percept option parp class
becom defin expand
tumor type backbon treatment
believ becom increasingli
valuabl larg pharma synergi io
also like increas investor percept
option especi ventur
rubraca ip like extend
rubraca composit matter expir
patent extend
exclus could target
obvious see sever practic bar
patent invalid gener competitor
enter estim
addit year exclus beyond
primari composit matter patent
expiri would add risk-adjust npv
key valuat driver clinic
commerci execut rubraca
success defens rubraca patent
earli rubraca zejula launch metric
azn data trial ovarian
risk achiev price
rubraca launch slower expect
rubraca fail on-going clinic trial
rubraca exclus lost earlier
pt includ us ex-u sale rucaparib rubraca multipl line
ovarian cancer treatment mainten therapi well valu rubraca use
breast prostat cancer includ risk-adjust npv
potenti use tumor type includ lung cancer head neck cancer
colorect cancer
exhibit risk-adjust valu molecul
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
clovi examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate line rest early-
termin growth rate model forecast revenu expens
opportun beyond assign termin valu nopat
drug/opportun
target epigenet driver diseas tazemetostat
target epigenet driver diseas tazemetostat
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
nopat deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
combin data show meaning improv efficaci without addit
toxic posit tazemetostat favor use part frontlin
treatment mainten regimen follicular lymphoma fl diffus
larg b-cell lymphoma dlbcl drive upsid current estim well
de-risk potenti larger frontlin opportun
see compel monotherapi activ drive tazemetostat use
relapsed/refractori r/r follicular lymphoma fl patient
mutat model peak sale probabl success use
fl repres valu use dlbcl repres po
rang see solid tumor use repres anoth
collabor celgen glaxo worth per share npv
failur multipl tazemetostat trial emerg signific safeti signal
lead share trade multipl cash
tazemetostat superl singl agent
activ follicular lymphoma patient
mutat view
compel data thu far tazemetostat
patient follicular
lymphoma fl mutat
drug object respons
rate orr monotherapi
combin data could key
unlock addit valu
on-going studi tazemetostat
combin rituxan prednisolon
agent tecentriq key catalyst
stock combin data
rituxan could unlock valu
frontlin treatment mainten
initi tazemetostat approv could
orphan solid tumor indic potenti
also test tazemetostat
number rare solid tumor could
repres fastest initi pathway
approv patient phase studi
epithelioid sarcoma es expect read
could form basi
anticip approv es
key valu driver perceiv clinic
regulatori risk tazemetostat
combo data tazemetostat rituxan
prednisolon tecentriq
submit nda acceler approv
neg epithelioid sarcoma
preliminari data phase trial
relapsed/refractori mesothelioma
risk achiev price
fail clinic trial tazemetostat
tazemetostat fail achiev consensu
potenti addit dilut financ
collabor fail result meaning
pt includ sale tazemetostat multipl line follicular lymphoma
fl diffus larg b-cell lymphoma dlbcl mutant wild-typ
wt patient pt also includ tazemetostat revenu solid tumor includ
epithelioid sarcoma neg solid tumor mesothelioma well
royalti potenti european partnership valuat also includ
per share risk-adjust npv compani collabor celgen
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate in-lin compani
histor wacc rest late development-stag biotechnolog univers
termin growth rate model forecast revenu expens
opportun assign termin valu nopat asset
epidiolex de-risk drive gwph share
epidiolex de-risk drive gwph share
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
epidiolex approv broad label allow use seizur associ
dravet syndrom lg meaning open door off-label
usag epidiolex launch scenario stronger-than-anticip
model higher penetr off-label opportun lead peak
epidiolex sale
epidiolex produc clinic meaning efficaci placebo dravet
lennox-gastaut model probabl success dravet syndrom
lg epidiolex indic peak sale
two orphan indic major revenu
come off-label usag cortic dysplasia refractori
multipl epidiolex trial failur lead stock trade approxim
multipl cash
overweight gwph believ
epidiolex approv wide use
treatment refractori pediatr
epilepsi on-label off-label
ww peak sale
regulatori risk initi gw focus
assess lessen time
market decreas regulatori risk
model epidiolex launch dravet
lg
phase dravet syndrom lg data
provid confid epidiolex clinic
program gw report posit top-lin
result first phase trial epidiolex
dravet syndrom two phase trial
lennox-gastaut syndrom believ
data meaning de-risk orphan
indic increment de-risk
model probabl success dravet
lg
main valuat driver perceiv
clinic regulatori risk epidiolex
commerci launch execut
cbdv data adult epilepsi
potenti adcom epidiolex
potenti epidiolex approv
risk achiev price
epidiolex emerg safeti issu
payer impos signific restrict
physician hesit prescrib
pt includ epidiolex usag label sever refractori epilepsi mostli
dravet syndrom lennox-gastaut tuber sclerosi meaning off-label
usag minim valu sativex ms spastic advanc cancer pain
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
gw examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate gw slightli compani
histor wacc
termin growth rate model forecast revenu expens
opportun beyond compani anticip orphan drug market
exclus europ assign termin valu
cash flow acknowledg early-stag pipelin advanc could
repres upsid valuat
jak backbon lucr partnership fuel oncolog platform ow thesi
lucr partnership fuel oncolog platform ow thesi
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
next blockbust emerg early-stag oncolog pipelin
increas probabl success epacadostat melanoma nsclc rcc
hnscc bladder tumor commerci out-performance jakafi
base case earlier anticip us approv baricitinib ra
provid increment upsid addit collabor tumor type
epacadostat drive valu
increas penetr myelofibrosi polycythemia vera continu
drive jakafi revenu peak sale fuel industry-
lead engin baricitinib us approv ra result peak
royalti view epacadostat earli oncolog
pipelin increasingli meaning potenti sale epacadostat
risk-adjust indic probabl success
multipl clinic failur advers impact probabl success
epacadostat addit early-stag oncolog asset jakafi underperform
appear unlik reach compani peak guidanc
baricitinib approv delay need sizabl outcom studi
jakafi provid stabl revenu backbon
revenu grow annual
patent expiri driven continu uptak
myelofibrosi polycythemia vera see
limit near-term threat revenu
epacadostat success repres upsid
base valuat believ epacadostat
promis compound capabl address
lung renal head neck bladder posit
data tumor type could lead
addit upsid forecast
driven commerci execut clinic
asset drug discoveri platform
uniqu mid-cap biotech sector
possess deep pipelin earli
clinic pre-clin asset addit
commerci revenu royalti stream
key valuat driver commerci
execut approv drug well
perceiv clinic regulatori risk
data brd pim program
phase data epacadostat/keytruda
melanoma
risk achiev price
jakafi uptak less anticip
baricitinib fail obtain approv and/or
clinic failur epacadostat
pt includ jakafi sale myelofibrosi mf polycythemia vera pv
royalti jakavi sale europ iclusig sale all/cml europ royalti
baricitinib sale rheumatoid arthriti atop dermat epacadostat sale
melanoma lung kidney head neck bladder cancer graft-versus-host diseas
gvhd b-cell malign includ risk-adjust npv
robust earli clinic pre-clin asset well drug discoveri engin
exhibit risk-adjust valu molecul
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate line compani
termin growth rate model forecast revenu expens
opportun beyond anticip exclus period product
product ip beyond expiri assign termin valu
million except per-shar data
total jakafi revenu
total baricitinib royalti
product revenu
total revenu
total revenu
risk pbc launch nash indic drive uw rate
risk pbc launch nash indic drive uw rate
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin vari commerci assumpt base/bull/bear
case assum wacc termin valu
cash flow deriv pt assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
ocaliva pbc minim impact safeti commun peak
sale higher base case assign favor
probabl success model nash revenu higher
base case base expans address market oca less
payor resist peak revenu nash scenario
us europ
ocaliva pbc launch temper gradual adopt due lack warehous
outcom data toler issu model nash probabl success
peak revenu us europ though believ
launch would measur due need market cultiv
emerg safeti concern lead regulatori action result revok
condit approv ocaliva market pbc regener
trial stop though risk program succeed increas
scenario assum multipl cash per share
underweight intercept
believ pbc launch nash risk
properli reflect share slow growth
new patient adopt pbc problem
enrol nash regener trial
indic weaker expect demand
market lack major posit
catalyst regener data
risk expect pbc
alphawis survey suggest viabl market
opportun oca pbc much smaller
compani guidanc price sensit
alphawis survey respond
found relat itch deterr oca
usag patient could stop
therapi toler issu seen
longer term see nash larg
larg inaccess market major
nash patient undiagnos
care primari care physician pcp
pcp would need refer patient
hepatologist order liver biopsi
patient elig treatment
short ip runway temper
launch think current estim much
optimist
main valuat driver
perceiv clinic regulatori risk
oca pbc nash commerci
launch execut pbc nash
ocaliva launch pbc on-going
initi phase trial nash patient
cirrhosi earli
potenti updat ocaliva label earli
competitor nash pbc data readout
risk achiev price
ocaliva launch pbc significantli exce
ocaliva produc better anticip
price target includ obetichol acid oca usag primari biliari
cholang pbc non-alcohol steatohepat nash primari scleros
cholang psc europ well royalti mileston oca
sale japan
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate line compani
histor wacc recent wacc
termin growth rate model forecast revenu expens
opportun assum oca exclus composit
matter patent expir plu year hatch-waxman extens recogn
would residu valu molecul potenti asset
explicitli model appli multipl cash flow account
termin valu
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin vari commerci assumpt base/bull/bear
case assum wacc termin valu
cash flow deriv pt assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
auryxia sale dialysi meaning acceler auryxia sale approxim
base scenario model peak sale us europ
scenario also includ keryx sign lucr european partnership fexer
captur sizabl up-front payment tier royalti start eu
auryxia launch challeng continu dialysi uptak temper
unfavor formulari placement lack compel differenti
model peak auryxia sale dialysi peak revenu
non-dialysi ckd expans indic attribut minim
valu less per share japan royalti mileston
partner jtt well minim valu potenti partnership europ
auryxia sale dialysi lower expect half base case
gener version current market leader renvela launch multipl
manufactur caus price share eros model peak sale
us europ
optimist label expans valuat keep us ew
optimist label expans valuat keep us ew
equal-weight kerx
optim auryxia sale growth label
expans temper concern around
margin need addit capit
optimist auryxia momentum label
expans weekli monthli prescript
auryxia shown good momentum
recent payor win secur favor
formulari posit current
expans indic optimist
current sale trajectori auryxia
potenti ckd
enthusiasm auryxia margin
fluctuat significantli compani
target cog significantli
higher tradit small molecul drug
cash equival
avail burn per
quarter believ addit capit like
need given number share
outstand potenti dilut convert
debt prefer sidelin
main valuat driver auryxia
commerci launch dialysi
perceiv clinic regulatori risk
auryxia ckd set
auryxia launch pre-dialysi ckd
transact
risk achiev price
expect driven strong sale dialysi
pre-dialysi ckd
auryxia fail gain signific uptak
fall short consensu expect
keryx fail obtain partnership
europ favor financi term
price target includ auryxia usag dialysi non-dialysi chronic kidney
diseas ckd well royalti mileston japan europ
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
keryx examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate kerx
termin growth rate model forecast revenu expens
opportun beyond compani anticip drug market exclus
patent protect us europ assign minim valu cash flow
beyond use multipl cash flow asset
pleuromutilin new class anti-infect cabp
pleuromutilin new class anti-infect cabp
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
nopat deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim
sum risk-adjust npv add cash excess requir
superl result leap trial provid clinic commerci
differenti oral lefamulin scenario model probabl
success lefamulin cabp along greater penetr
inpati outpati set result peak us sale
see lefamulin use expans indic ex-u
see uptak lefamulin driven use iv formul inpati
set lead meaning use oral form hospit discharg
set model peak lefamulin sale probabl
success follow posit result phase leap trial assign
lefamulin expans indic potenti ex-u
failur lefamulin clinic program due lack efficaci emerg
signific safeti signal lead share trade discount current net cash
estim
lefamulin novel mechan action
provid need option cabp nabriva
lefamulin first-in-class system
pleuromutilin develop oral iv
use treat community-acquir bacteri
pneumonia cabp lefamulin cabp
target spectrum activ novel
mechan action resist seen
date provid import altern
option treatment cabp
confid upcom leap trial
posit result phase leap trial
septemb trial studi iv
show non-inferior lefamulin
confid second phase
readout leap trial expect spring
base leap result
expect gradual commerci adopt
lefamulin driven use inpati
set nabriva initi target
inpati set sale rep
target highest prescrib
hospit repres cabp
treatment gain formulari access
key highli competit generic
market see peak lefamulin sale
key valu driver perceiv clinic
regulatori risk lefamulin
data phase studi oral
cabp spring
nda submiss lefamulin cabp
risk achiev price
fail clinic trial lefamulin
lefamulin sale fail achiev consensu
potenti addit dilut financ
pt includ us lefamulin sale community-acquir bacteri pneumonia
cabp inpati outpati set includ hospit discharg
prescript well anticip royalti sale lefamulin outsid us
also includ risk-adjust npv per share addit lefamulin
sti pediatr use
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
nabriva examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate nbrv in-lin compani
histor wacc rest late development-stag biotechnolog univers
termin growth rate model forecast revenu expens
opportun assign termin valu nopat asset
million except per-shar data
total research premium grant revenu
research develop
gener administr
move sidelin increas uncertainti
move sidelin increas uncertainti
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
nopat deriv pt assign probabl factor
drug\condit reflect clinic regulatori risk sum
risk-adjust npv add cash excess requir invest
ocular resolv manufactur issu dextenza obtain approv
post-surg indic de-risk addit aspect platform
assum probabl success otx-tp glaucoma also give
greater credit technolog platform applic indic
assum po probabl success dextenza post-op
pain inflamm po otx-tp glaucoma po
allerg conjunct assign valu ocular earlier-stag
program vegf otx-mp technolog platform
multipl clinic trial failur allerg conjunct post-op inflamm
lead program discontinu re-risk technolog platform
equal-weight ocular new
manag continu address
manufactur regulatori issu
dextenza given uncertainti around
manufactur issu dextenza
path ahead prefer sidelin
fda juli relat
persist issu along recent
turnov manag increas
uncertainti around technolog platform
main valuat driver perceiv
clinic regulatori risk otx-tp
dextenza vegf platform
commerci launch execut
regulatori feedback manufactur
dextenza nda resubmiss
dextenza potenti us launch
risk achiev price
dextenza gain approv earlier
dextenza otx-tp clinic studi fail
regeneron exercis option vegf
price target includ sale resur sealant altern stitch
ocular surgeri dextenza treatment post-op pain/inflamm
allerg conjunctivitis/dri eye otx-tp treatment glaucoma well valu
deriv earlier stage program vegf hydrogel platform technolog
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate high end rang
compani coverag univers rang
termin growth rate model forecast revenu expens
opportun appli multipl nopat account
termin valu asset
commerci challeng drag share
commerci challeng drag share
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin vari commerci assumpt base/bull/bear
case assum wacc termin valu
cash flow deriv pt assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
faster-than-anticip uptak trifer format partnership
current competitor freseniu lead broad adopt trifer
calcitriol scenario also includ lucr ex-u partnership
trifer provid larg up-front payment favor royalti
sale model peak sale trifer scenario
estim peak sale trifer model uptak small dialysi
chain independ oper model approx per share valu
base busi hemodialysi concentr anoth per share
residu cash
trifer fail gain commerci accept signific dialysi provid
calcitriol launch and/or gain accept among
provid base busi experi signific issu partner baxter
underweight given believ
rockwel trifer unlik
experi meaning usag dialysi
major dialysi clinic use vat instead
jug extern consult
alphawis survey confirm major
dialysi clinic switch individu
jug central vat trifer suppli
individu vial make usag larg
vat cumbersom potenti increas
risk infect
pilot necessari prior widespread
adopt use trifer vat would provid
iron patient dialysi center
current practic prior adopt trifer
would necessari confirm safeti
well financi feasibl
dialysi center need confirm epo
spare bundl dialysi
center extrem cost-sensit
rockwel trial show epo spare
flaw indic anticip
real-world experi note fda
deni trifer epo spare label
pilot studi like necessari
would take month gener
main valuat driver commerci
launch execut trifer
decis transit add-on
payment trifer
commerci launch powder form
resolut calcitriol manufactur
risk achiev price
freseniu wide adopt trifer
without need lengthi pilot studi
price target includ sale trifer hemodialysi concentr
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate
termin growth rate model forecast revenu expens
opportun appli multipl cash flow account
termin valu asset
promis data target genet link obes
promis data target genet link obes
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
nopat deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim
sum risk-adjust npv add cash excess requir
setmelanotid data bardet-biedl syndrom bb exceed expect
de-risk opportun clinic data alstrom syndrom
pomc heterozyg defici establish human proof concept
expans indic probabl success setmelanotid increas
pomc lepr bb expans
compel efficaci data provid confid setmelanotid pomc
lepr defici obes model probabl success
respect data bardet-biedl syndrom largest valu driver
model appear promis remain less compel assum
probabl success estim peak sale setmelanotid
assign minim valu per share potenti expans indic
multipl fail clinic trial and/or emerg signific safeti issu
setmelanotid result stock trade multipl cash
compel efficaci setmelanotid
two ultra-orphan diseas may result
first-in-class agonist setmelanotid
demonstr compel efficaci pomc
lepr defici two ultra-orphan
pomc trial result publish
prestigi new england journal medicin
juli
bardet-biedl larger opportun
though data gener date less
compel thu far rhythm pursu
bardet-biedl syndrom third indic
setmelanotid potenti larger
indic rel pomc lepr
defici mani patient
alreadi diagnos consequ
associ morpholog featur clinic
compel updat phase
studi anticip believ
may key catalyst share
increas diagnosi genet link
obes key commerci success
import lever setmelanotid commerci
success view increas test
diagnosi rate genet disord
obes patient target
ideal candid setmelanotid therapi
current undiagnos
anticip avail therapeut
would help increas test diagnosi
rate believ rhythm need invest
meaning captur patient
realiz potenti market opportun
key valuat driver perceiv
clinic regulatori risk setmelanotid
pomc defici obes lepr defici
syndrom pomc heterozyg obes
complet enrol phase pomc
defici trial
initi clinic data addit indic
alstrm pomc hetz
risk achiev price
fail clinic trial setmelanotid
rhythm unabl enrol pivot trial
orphan indic
pt includ us/eu sale setmelanotid treatment pomc
defici obes leptin receptor defici obes bardet-biedl syndrom
bb attribut minim valu program alstrm syndrom pomc
heterozyg obes orphan obes indic pend proof concept
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate in-lin rest
termin growth rate model forecast revenu expens
opportun assign termin valu nopat asset
aim upper echelon
aim upper echelon
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc ebit deriv
npv assign probabl factor drug/condit
reflect clinic regulatori risks/tim sum risk-adjust
npv add cash excess requir invest
label expans drive acceler deeper expans earlier
line hodgkin lymphoma model peak sale adcetri
frontlin hodgkin greater adopt patient earlier-stag diseas
result peak total adcetri sale exceed compound-annual-growth-rate clinic
commerci execut drive investor enthusiasm well increas
prospect strateg option
adcetri uptak establish indic r/r hodgkin lymphoma salcl
post-transpl hl set continu model probabl
success label expans opportun frontlin hl
probabl success mtcl us sale adcetri
reach compound-annual-growth-rate
adcetri fail gain label expans frontlin hodgkin lymphoma
mtcl set neg impact uptak
establish indic includ post-transpl consolid aethera
set percept strateg option declin increas skeptic
around compani platform technolog
revenu backbon adcetri approv
usag third-lin agent
transplant hodgkin lymphoma hl
well anoth rare lymphoma salcl
see risk current indic i/o
agent immateri extern
consult indic increas usag
drug transplant durat
therapi line
expans opportun commerci
execut drive share near
penetr transplant set
aethera expans ctcl
alcanza provid near-term growth
expans frontlin hl
believ success expans
peak us sale strateg
option like remain part
key valuat driver clinic
commerci execut adcetri
fda decis pdufa date adcetri
frontlin hl
risk achiev price
adcetri revenu fail meet consensu
fail clinic trial adcetri
collabor fail result meaning
pt includ us adcetri sale ex-us/ca royalti multipl line
hodgkin lymphoma hl includ current approv third-lin post-transpl
consolid well second-lin off-label retreat multipl line off-
label frontlin indic pt also includ sale adcetri
salcl ctcl mtcl dlbcl well sale aml
includ risk-adjust npv robust earli
clinic pipelin pre-clin asset risk-adjust npv antibodi
drug conjug technolog collabor
exhibit risk-adjust valu molecul
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate line compani
histor wacc rest early-commerci biotechnolog univers
termin growth rate model forecast revenu expens
opportun beyond assign termin valu nopat
drug/opportun
zejula post signific uptak
ovarian cancer mainten broad clean
label trial niraparib activ
mutat subgroup ovarian cancer
anticip drug like
grant broad label regulatori
author signific
advantag commerci provid
larger market opportun less
parp inhibitor restrict activ
parp retreat enabl parp
expand multipl line therapi
think size ovarian cancer
opportun under-appreci especi
likelihood niraparib use
multipl line therapi ovarian
retreat assumpt rel
approxim tsro valu
current assum retreat
revenu tumor type
follow fda approv percept
option could increas
knowledg potenti transact
manag comment
believ plausibl investor percept
strateg option could increas
follow fda approv zejula
key valuat driver clinic
commerci execut niraparib varubi
pipelin drug
lynparza phase data ovarian
cancer mainten brca
niraparib phase quadra data
ovarian cancer treatment
data
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin valu
nopat deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
zejula stronger expect commerci uptak ovarian cancer
outperform base case parp combin chemo
immuno-oncolog show strong activ wide rang tumor expand
platform opportun clinic data indic broad potenti parp
zejula niraparib robust uptak follow broad approv
mainten ovarian cancer addit trial ovarian cancer allow
expans set within diseas model probabl
success frontlin mainten prima fourth line treatment
quadra data set tumor type phase bravo trial
breast cancer allow expans beyond ovarian cancer
niraparib clinic trial fail opportun tumor expans limit
parp fail lung pancreat prostat cancer parp combin
regimen toler signific resist prevent meaning parp
risk achiev price
zejula revenu fail meet expect
fail trial ovarian breast lung
pt includ us ex-u sale varubi chemotherapi induc nausea
vomit cinv sale niraparib multipl line ovarian cancer
treatment mainten therapi well valu niraparib use breast
prostat cancer includ risk-adjust npv usag
niraparib tumor type explicitli model includ lung head
neck pancreat cancer also includ risk-adjust npv
tesaro promis early-stag immuno-oncolog i/o pipelin asset
exhibit tsro valu broad indic
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
tesaro examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate tsro line rest early-
termin growth rate model forecast revenu expens
opportun beyond assign termin valu nopat
drug/opportun
million except per-shar data
licens collabor revenu
cost expens
sale
research develop
gener administr
acquir in-process research develop
regulatori uncertainti
overhang receiv
complet respons letter fda
may cite lack long
term safeti data beyond week rejoic
studi compani
dialogu agenc submit
addit data resolut pathway
unclear think share like
range-bound pend clariti
alphawis survey indic
dyspareunia posit differenti
though consensu expect lofti
august alphawis survey us
ob/gyn show physician view
posit differenti
physician survey indic
intend prescrib
approxim number
dyspareunia patient
consensu exce
sale nearli peak
target sizabl
attract market vm expect
would fda-approv oral bio-
treatment vm hot flash
relat menopaus multi-billion
dollar market compris larg
pharmaci intend partner
gain share see penetr
market model sale
though less consensu
expect
key valuat driver perceiv
clinic regulatori risk pipelin asset
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
gain time approv without need addit studi
commerci launch approx current estim issu identifi
nda submiss addit agreement compound
pharmaci provid confid captur larg segment
regulatori uncertainti persist model probabl
success launch result sale late
launch vm result peak sale sizabl
opportun current consensu
fail gain time approv fda requir addit
month trial fulli character endometri safeti assum
probabl success launch regulatori issu emerg
lower probabl success
well
commerci launch execut
product obtain approv
fda decis pdufa date
updat potenti debt financ
risk achiev price
fail gain time approv
fda request addit month
gain time approv
launch disappoint rel consensu
gain time approv
potenti need dilut financ
pt includ us sale treatment dyspareunia tx-
treatment vasomotor symptom vm compani base
busi prenat vitamin
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate gener in-lin
compani histor wacc rest biopharmaceut univers
revenu commerci product
termin growth rate model forecast revenu expens
opportun prenat vitamin busi calcul termin valu
million except per-shar data
cost expens
sale
sale gener administr
research develop
depreci amort
await strateg updat path forward
await strateg updat path forward
deriv pt risk-adjust sotp forecast expect
revenue/profit drug/condit combin vari
commerci assumpt base/bull/bear case assum
discount rate use termin valu deriv pv
assign probabl factor drug/ind reflect clinic
regulatori risks/tim sum risk-adjust npv add
develop adult ghd succe market somavaratan larger
anticip somavaratan also commerci success japan
lead larger anticip royalti
somavaratan develop continu adult ghd assign probabl
success po see peak sale assign similar probabl
success japan result royalti peak note
valuat line compani current cash per share
versarti unabl conserv cash and/or pursu addit somavaratan
develop work result meaning commerci revenu
addit partnership assum per share residu cash valu
equal-weight vsar await
strateg updat path forward
phase veloc studi pediatr
vsar financi suggest per share
net cash focu conserv cash
resourc follow phase veloc
provid addit guidanc
compani intend invest
main valuat driver perceiv
clinic regulatori risk somavaratan
strateg updat somavaratan
present somavaratan phase
veloc data upcom medic
risk achiev price
discontinu somavaratan
invest cash resourc
result meaning revenu
price target includ sale somavaratan use adult growth hormon
defici ghd well royalti sale somavaratan japan
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
versarti examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate vsar
termin growth rate model forecast revenu expens
opportun appli multipl cash flow account
termin valu asset
pipelin better peptid
pipelin better peptid
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
superior data differenti glepaglutid dasiglucagon
competit acceler uptak zealand advanc addit candid
clinic soliqua take domin posit develop
soliqua uptak grow broaden insur coverag dasiglucagon
glepaglutid compet share establish player zealand
proprietari partner asset advanc
zealand candid suffer clinic setback fail reach market
zealand unabl discov new candid soliqua growth weaker
expect remain focu investor zealand partnership struggl
compani unabl sign new collabor
pharma valid revenu backbon
diabet drug adlyxin soliqua
market sanofi leader space
zealand collect revenu sale
drug support oper importantli
buy-in market leader like sanofi
valid zealand platform peptid
longer half life better stabil could
differenti glepaglutid short bowel
syndrom glepaglutid next-gen
agonist develop sb shire gattex
earlier record
sale despit sub-optimal profil
featur short half life need
glepaglutid enhanc stabil
extend half life allow drug
preformul advantag believ
drive patient uptak may produc
dasiglucagon stabil look better
option us sever hypoglycemia
market dasiglucagon stabl readi use
form peptid glucagon
develop rescu medic sever
hypoglycemia current market
domin glucagon poor solubl
stabil requir reconstitut
emerg use believ
dasiglucagon eas use drive
signific uptak rescu market
potenti futur use artifici pancrea
system orphan indic congenit
hyperinsulin chi repres upsid
estim
key valuat driver commerci
execut partner diabet product
soliqua/adlyxin well perceiv clinic
regulatori risk pipelin asset
dasiglucagon glepaglutid
pk data weekli glepaglutid
initi phase trial glepaglutid
quarterli sale partner diabet
risk achiev price
sale partner diabet product
rel expect remain focu
fail clinic trial pipelin candid
dasiglucagon glepaglutid
collabor fail result meaning
pt includ royalti partner sanofi ww sale
combin product soliqua us/eu sale glepaglutid treatment
short bowel syndrom sb us sale dasiglucagon treatment sever
hypoglycemia insulin shock attribut minim valu royalti sanofi
ww sale adlyxin/lyxumia compani earlier stage program includ
dasiglucagon use dual-hormon artifici pancrea treatment chronic
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
zealand pharma examin clinic regulatori commerci risk
opportun individu indic region assign probabl
success account likelihood achiev revenues/expens
discount rate use discount rate zeal in-lin compani
histor wacc rest early-commerci biotechnolog univers
termin growth rate model forecast revenu expens
opportun assign termin valu nopat asset
